An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective

BACKGROUND: Treatment cycling with biologic disease-modifying anti-rheumatic drugs, such as tumor necrosis factor inhibitors (TNFi), is common among patients with rheumatoid arthritis (RA) and can result in reduced clinical efficacy and increased economic burden. Tofacitinib is an oral Janus kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Claxton, Lindsay, Taylor, Matthew, Soonasra, Arif, Bourret, Jeffrey A., Gerber, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397979/
https://www.ncbi.nlm.nih.gov/pubmed/29897007
http://dx.doi.org/10.18553/jmcp.2018.17220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397979/
https://www.ncbi.nlm.nih.gov/pubmed/29897007
http://dx.doi.org/10.18553/jmcp.2018.17220

Ejemplares similares